Change of Director's Interest Notice TM  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Investor Presentation  
 
    Technegas USA Trial Successfully Meets Primary Endpoint  
 
    CYC Partners With McMasters University In COVID-19 Research  
 
    Half Year 2020 Financial Results  
 
    Half Yearly Report and Accounts  
 
    Dividend/Distribution - CYC  
 
    Change of Director's Interest Notice  
 
    Appendix 2A  
 
    Results of Meeting  
 
    Managing Director's Address to Shareholders  
 
    CYC 2020 AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    CYC 1H2020 Business Update  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Technegas Approved in Russia - Clarification  
 
    USFDA Approval to File Received for Technegas  
 
    Technegas Approved in Russia  
 
    Final share buy-back notice - Appendix 3F  
 
    Form 484 cancellation of Long Term Incentive Plan shares  
 
    Appendix 2A  
 
    USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver  
 
    CYC Appendix 4G  
 
    Annual Report to shareholders  
 
    Cyclopharm Lodges NDA for Technegas with the USFDA  
 
    Cyclopharm Company Update  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Investor Presentation  
 
    Change of Director's Interest Notice  
 
    Preliminary Final Report  
 
    Dividend/Distribution - CYC  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Becoming a substantial holder  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    CYC Institutional Placement - Premium To Share Price  
 
    AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS  
 
    Trading Halt  
 
    Pause in Trading  
 
    Appendix 3B  
 
    Change of Director's Interest Notice JM  
 
    Appendix 3B  
 
    CYC Business Update  
 
    Final Director's Interest Notice  
 
    Board Update  
 
    Cyclopharm Investor Presentation - TechKnow Invest Roadshow  
 
    Cyclopharm Strengthens Leadership Team  
 
    CYC Half Yearly Reports and Accounts  
 
    Dividend/Distribution - CYC  
 
    Cyclopharm Investor Presentation - Bioshares 2019  
 
    Change of Director's Interest Notice - TM  
 
    Change of Director's Interest Notice - TM  
 
    Appendix 3B LTIP  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Announcement of buy-back - Appendix 3C  
 
    Results of Meeting  
 
    Managing Director's Address to Shareholders  
 
    CYC 2019 AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    Final share buy-back notice - Appendix 3F  
 
    Notice of General Meeting/Proxy Form  
 
    Cyclopharm Investor Presentation  
 
    Change of Director's Interest Notice  
 
    CYC Appendix 4G  
 
    Annual Report to shareholders  
 
    Dividend/Distribution - CYC  
 
    Preliminary Final Report  
 
    CYC Update - R&D Tax Incentive, USFDA, German Litigation  
 
    CANM Endorses Technegas  
 
    CYC - FNN Interview  
 
    Positive USFDA Meeting - Technegas sales expected in 2019  
 
    CYC Form 484 Cancellation of Long Term Incentive Plan shares  
 
    Change of Director's Interest Notice VG  
 
    Response to ASX Appendix 3Y Query  
 
    Change of Director's Interest Notice VG  
 
    Cyclopharm FNN Investor Event  
 
    Dividend/Distribution - CYC  
 
    CYC Half Yearly Reports and Accounts  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Cyclopharm 2018 First Half Preliminary Headline Update  
 
    Appendix 3B LTIP  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice - Amended  
 
    Change of Director's Interest Notice  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Announcement of buy-back - Appendix 3C  
 
    Results of Meeting  
 
    CYC 2018 AGM Presentation  
 
    Managing Director's Address to Shareholders  
 
    Chairman's Address to Shareholders  
 
    Final share buy-back notice - Appendix 3F  
 
    Better Defining Airways Disease with Technegas  
 
    Cyclopharm Acquires Scandinavian Distribution Business  
 
    Notice of Annual General Meeting/Proxy Form  
 
    40 Patient Milestone Achieved For Technegas USFDA Trial  
 
    CYC Appendix 4G  
 
    Annual Report to shareholders  
 
    2017 Results Presentation  
 
    Change of Director's Interest Notice - David Heaney  
 
    CYC Reports Solid FY2017 Results - Maintains Dividend  
 
    Preliminary Final Report  
 
    Dividend/Distribution - CYC  
 
    FNN Interview and Presentation  
 
    Cyclopharm FNN Investor Event  
 
    Change of Director's Interest Notice - D Heaney  
 
    CYC CEO Presentation 2017 Australian Microcap Conference  
 
    Technegas USFDA Clinical Trial - Patient Enrolment Underway  
 
    Cyclopharm acquires European distribution business  
 
    Advancing Molecular Imaging in NSW  
 
    Form 484 - cancellation of Long Term Incentive Plan shares  
 
    Cyclopharm Limited 1H2017 Results Investor Presentation  
 
    Dividend/Distribution - CYC  
 
    Nuclear imaging trial aiming to clear up airway diagnosis  
 
    CYC CEO To Present at Bioshares 2017 Biotech Conference  
 
    Change in substantial holding - Chemical Trustee Limited  
 
    Change in substantial holding - Barings Acceptance Limited  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from AEF  
 
    Change of Director's Interest Notice - JMcBrayer  
 
    Change of Director's Interest Notice - VGould  
 
    Change of Director's Interest Notice - D Heaney  
 
    Appendix 3B Final  
 
    CYC Entitlement Offer Closed  
 
    CYC Notification of Shortfall  
 
    CYC Entitlement Offer Booklet  
 
    Letter to Ineligible Shareholders  
 
    Letter to Eligible Shareholders  
 
    Appendix 3B  
 
    Cleansing Statement  
 
    Entitlement Offer  
 
    Response to ASX query on Appendix 3Y  
 
    CYC - Positive Results of China Clinical Trial  
 
    Change of Director's Interest Notice  
 
    CYC May 2017 Investor Presentation  
 
    Announcement of buy-back - Appendix 3C  
 
    Results of Meeting  
 
    Managing Director's Address to Shareholders  
 
    Chairman's Address to Shareholders  
 
    CYC 2017 AGM Presentation  
 
    Final share buy-back notice - Appendix 3F  
 
    Appendix 3B  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Initial Director's Interest Notice  
 
    CYC Board Changes  
 
    CYC Appendix 4G  
 
    Change in substantial holding from CVC  
 
    Becoming a substantial holder - AACCF (Amended)  
 
    CYC 2016 Financial Year Results Investor Presentation  
 
    Ceasing to be a substantial holder - Lloyds (Amended)  
 
    Cyclopharm Amended 2016 Preliminary Financial Report  
 
    Dividend/Distribution - CYC  
 
    Preliminary Final Report  
 
    Becoming a substantial holder - AACCF  
 
    Ceasing to be a substantial holder - Lloyds  
 
    CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS  
 
    Release Date of 2016 Full Year Preliminary Financial Results  
 
    Change of Director's Interest Notice  
 
    CYC Achieves USFDA Agreement For Technegas Trial Design  
 
    Change of Company Address  
 
    Becoming a substantial holder from AEF  
 
    Cyclopharm CEO Microcap Investment Conference Presentation  
 
    Cyclopharm Business Update on Significant Milestones  
 
    Chairman to Stand Down Temporarily  
 
    CYC Share Registry Details  
 
    Cyclopharm Limited 1H2016 Results Investor Presentation  
 
    Dividend/Distribution - CYC  
 
    CEO Presentation at BioShares BioTech Summit 2016  
 
    Appendix 3B LTIP  
 
    Cyclopharm Investor Presentation 21 July 2016  
 
    CYC Strengthens Mgt Depth and Expands Clinical Expertise  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    CYC Signs Agreement with the Canadian Association of Nuc Med  
 
    Trading Update & Record Technegas Order Received from China  
 
    Change of Share Registry address  
 
    Announcement of buy-back - Appendix 3C  
 
    Board Changes / Appendix 3Z  
 
    Results of Annual General Meeting  
 
    Managing Director's Report  
 
    Managing Director's AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    Cyclopharm to Proceed Independently with FDA Trials  
 
    Appendix 4G  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Cyclopharm Limited Investor Presentation  
 
    Dividend/Distribution - CYC  
 
    Strong Technegas Earnings Underpin Record Profit  
 
    Preliminary Final Report  
 
    Technegas COPD Trial Update  
 
    Cyclopharm receives insurance settlement  
 
    Cyclopharm receives insurance settlement  
 
    Response to ASX query re Appendix 3Y  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change in substantial holding from CVC  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Pays Maiden Dividend  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Launches World-First Nuclear Medicine Technology  
 
    CYC Investor Presentation 7 October 2015  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change in substantial holding from CVC  
 
    Change of Director's Interest Notice  
 
    Managing Director's Address to Investors  
 
    Cyclopharm signs Term Sheet with Jubilant Draximage  
 
    Dividend/Distribution - CYC  
 
    Cyclopharm Unveils Inaugural Dividend  
 
    CYC Investor Presentation July 2015  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Change of Share Registry Name  
 
    Results of Meeting  
 
    Managing Director's Report  
 
    Managing Director's AGM Presentation  
 
    Chairman's Address to Shareholders  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Investor Presentation  
 
    Cyclopharm Reports Record Profit  
 
    Preliminary Final Report  
 
    Response to ASX Query  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Share Registry address  
 
    Form 484 - cancellation of Long Term Incentive Plan shares  
 
    Form 484 Cancellation of Long Term Incentive Plan shares  
 
    Update on Cyclotron Facility  
 
    Appendix 3B  
 
    Results of Mediation  
 
    Change of Director's Interest Notice  
 
    Cyclotron Facility Suffers Significant Water Damage  
 
    Results of Meeting  
 
    Managing Director's Report  
 
    Chairman's Address to Shareholders  
 
    Managing Director's AGM Presentation  
 
    Chairman Reinstated  
 
    Notice of Annual General Meeting/Proxy Form  
 
    2013 Annual Report  
 
    Cyclopharm to cease Cyclotron commercial operations  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Amended Appendix 3X  
 
    Change of Director's Interest Notice  
 
    Preliminary Final Report  
 
    Change of Director's Interest Notice  
 
    Japanese Regulatory Approval received  
 
    Chairman to Stand Down Temporarily  
 
    Change of Director's Interest Notice  
 
    Letter to shareholders  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Director Appointment/Resignation  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    2013 Half Yearly Report and Accounts  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    MMI Research Revolutionises The Study of Ancient Artefacts  
 
    Results of Meeting  
 
    Managing Director's AGM Presentation  
 
    Managing Director's Report  
 
    Chairman's Address to Shareholders  
 
    Change in substantial holding  
 
    Technegas May Facilitate Earlier Diagnosis of COPD  
 
    Cyclopharm Develops New Nuclear Medicine Technology  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change of Director's Interest Notice  
 
    Form 484 - cancellation of Long Term Incentive Plan shares  
 
    Annual Report to shareholders  
 
    Change of Director's Interest Notice  
 
    Preliminary Final Report  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Despatch of Holding Statements  
 
    Appendix 3B Rights Issue  
 
    Rights Issue - Despatch of Offer Documents  
 
    Technegas Clinical Trial - First Patient Enrolled  
 
    Entitlement and Acceptance Form  
 
    Offer Booklet  
 
    Cleansing Notice  
 
    Appendix 3B  
 
    Letter to Ineligible Shareholders  
 
    Letter to Eligible Shareholders  
 
    Renounceable Issue  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Change in substantial holding  
 
    Half Yearly Report and Accounts  
 
    Cyclopharm Files Claim Against ANSTO  
 
    Update on Share Consolidation  
 
    AGM Presentation Audio Broadcast  
 
    Results of Annual General Meeting  
 
    Managing Director's Report  
 
    Chairman's Address  
 
    AGM Presentation  
 
    Notice of Annual General Meeting/Proxy Form  
 
    ANSTO Subsidiary in breach of Competitive Neutrality Rules  
 
    Annual Report to shareholders  
 
    Director Appointment/Resignation  
   
    Preliminary Final Report  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    MUH becomes Shareholder in CYC Imaging Joint Venture  

 
    Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Cyclopharm Receives Approval from United States FDA  
 
    Correction - Number of Issued Shares  
 
    Rights Issue - Despatch of Holding Statements  
 
    Completion of Rights Issue and Notice of Under Subscriptions  
 
    Entitlement and Acceptance Form  
 
    Offer Booklet for Renounceable Rights Issue  
 
    Cleansing Notice  
 
    Unmarketable Parcel Sale Facility  
 
    Appendix 3B  
 
    Letter to Ineligible Shareholders  
 
    Letter to Eligible Shareholders  
 
    Renounceable Rights Issue and Sale of Unmarketable Parcels  
 
    Renewal of Debt Facility with National Australia Bank  
 
    Amended Change of Director's Interest Notice  
 
    Change of Director's Interest Notice  
 
    Half Yearly Report and Accounts  
 
    Trading Update  
 
    Director Appointment/Resignation  
 
    Change in substantial holding  
 
    Change of Registered Office Address  
 
    Change in substantial holding  
 
    AGM Presentation Audio Broadcast  
 
    AGM Presentation  
 
    Managing Director's Report  
 
    Chairman's Address to Shareholders  
 
    Initial Director's Interest Notice  
 
    Director Appointment/Resignation  
 
    Notice of General Meeting/Proxy Form  
 
    Company Secretary Appointment/Resignation  
 
    Annual Report to shareholders  
 
    Preliminary Final Report  
 
    Clinical Protocol Approval from US FDA  
 
    Diversity Policy  
 
    Share Trading Policy  
 
    Cyclopet sells commercial FDG doses  
 
    Change of Director's Interest Notice  
 
    Cyclopet receives TGA License  
 
    Change in substantial holding  
 
    Half Yearly Report and Accounts  
 
    Company Update  
 
    Change of Director`s Interest Notice  
 
    Regulatory Approval in China  
 
    2010 AGM Presentation - Audio Broadcast  
 
    Results of Meeting  
 
    Chairman`s Address  
 
    Managing Director`s Presentation  
 
    AGM Presentation  
 
    Change in substantial holding  
 
    Notice of General Meeting/Proxy Form  
 
    2009 Annual Report  
 
    Preliminary Final Report  
 
    Change of Director`s Interest Notice  
 
    Cyclopharm settles claim for US$1.8m  
 
    Change in substantial holding from CVC  
 
    Change of Director`s Interest Notice  
 
    Cyclotron delivered to Macquarie University Hospital  
 
    Change of Director`s Interest Notice  
 
    Response to an ASX Query - Director`s Interest Notices  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    2009 Half Yearly Report and Accounts  
 
    CYC enters into Medical Imaging JV- Audio Broadcast  
 
    Cyclopharm enters into Medical Imaging Joint Venture  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    2009 AGM Presentation - Audio Broadcast  
 
    Results of Meeting  
 
    Chairman`s Address  
 
    Managing Director`s Presentation  
 
    AGM Presentation  
 
    Company Update  
 
    Notice of General Meeting/Proxy Form  
 
    2008 Annual Report  
 
    Full Year Presentation - Audio Broadcast  
 
    Change of Director`s Interest Notice  
 
    Full Year Presentation  
 
    Final Director`s Interest Notice  
 
    Preliminary Final Report  
 
    Profit Upgrade  
 
    Resignation of Director  
 
    Change in substantial holding  
 
    Change in substantial holding from CVC  
 
    Lodgement of application to sell Technegas in United States  
 
    Company Update  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Allotment of Rights Issue Shares  
 
    Closure of Rights Issue  
 
    Amendment to Dispatch Rights Issue Offer Document  
 
    Rights Issue - Dispatch Offer Document  
 
    Rights Issue - Offer Document  
 
    Rights Issue - Cleansing Statement  
 
    Amended Appendix 3B  
 
    Amended Rights Issue Timetable  
 
    Appendix 3B  
 
    Announcement of Offer  
 
    Change in substantial holding  
 
    Investor Presentation - Audio Broadcast  
 
    Investor Presentation  
 
    Half Year Presentation  
 
    2008 Half Yearly Report and Accounts  
 
    Government expands PET approved indications  
 
    Initial Director`s Interest Notice  
 
    Appendix 3B  
 
    Change of Director`s Interest Notice  
 
    Change in substantial holding  
 
    Confirmation of appointment of new Managing Director  
 
    2008 AGM Presentation - Audio Broadcast  
 
    Cyclopharm receives regulatory approval in Brazil  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    AGM Presentation  
 
    Results of Meeting  
 
    Change in substantial holding  
 
    Change of Director`s Interest Notice  
 
    Amended Appendix 3Y released 25 March 2008  
 
    Change in substantial holding  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Change of Director`s Interest Notice  
 
    Change in substantial holding  
 
    Annual Report to shareholders  
 
    Cyclopharm Limited achieves a major milestone in Sydney  
 
    Full Year Result and Company Update - Audio Broadcast  
 
    Preliminary Final Report  
 
    Cyclopharm makes its first sale in Russia  
 
    Director Appointment/Resignation  
 
    Cyclopharm achieves a major milestone  
 
    Regulatory Approval in Italy  
 
    Change in substantial holding from CVC  
 
    Change of Director`s Interest Notice  
 
    Change of Director`s Interest Notice  
 
    Half Year Presentation  
 
    2007 Half Yearly Report and Accounts  
 
    Change of Director`s Interest Notice  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding from CVC  
 
    Change in substantial holding  
 
    Appendix 3B  
 
    Change of Director's Interest Notice  
 
    Managing Directors AGM Presentation  
 
    Minutes of AGM  
 
    Notice of Annual General Meeting  
 
    2006 Annual Report  
 
    Preliminary Final Report  
 
    Becoming a substantial holder  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Constitution  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder from CVC  
 
    Audio Broadcast  
 
    Amended Media Release  
 
    Media Release  
 
    Amended notice re Admission to Official List  
 
    Admission to Official List  
 
    Appendix 1A: ASX Listing application and agreement  
 
    Statement from Directors  
 
    CYC - Interim Report June 2006  
 
    CYC - Financial Report 2004  
 
    ASX Circular: Commencement of Official Quotation  
 
    Distribution Schedule  
 
    Top 20 shareholders  
 
    Financial Report 31 December 2005  
 
    Financial Report December 2003  
 
    Prospectus  
 
    Supplementary Disclosure Document